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                                      Cisplatin is a mainstay in the treatment of a variety of solid 
tumors, notably testicular cancer. The major toxic side effects 
include nephrotoxicity, peripheral neurotoxicity, and ototoxicity 
(  1  ). Inner ear toxicity, which may result in disabling hearing loss 
and tinnitus, is often a dose-limiting side effect that hampers 
optimal cisplatin-based chemotherapy. Ototoxicity has a general 
dose dependence but with considerable interindividual variabil-
ity. The main targets of the ototoxicity are the outer hair cells in 
the organ of Corti and the vascularized epithelium in the lateral 
wall of the cochlea, the stria vascularis (  2  ). Cisplatin induces a 
caspase-dependent apoptotic pathway in sensitive cochlear cells 
(  3  ). The molecular mechanisms that trigger apoptosis in the 
cochlea have not been elucidated, but several mechanisms have 
been proposed that appear to involve increased oxidative stress 
(  2  ,  4  ). The organ of Corti is hidden in the deep compartment of 
the inner ear and is protected by a blood  –  labyrinth barrier. This 
barrier restricts the entry of cisplatin to the perilymphatic com-
partment of the inner ear and can thereby dampen the effects of 
short peaks in the concentration of cisplatin in the systemic cir-
culation (  5  ). 
  Oxaliplatin is a third-generation platinum-based drug that is 
used predominantly for treatment of colorectal carcinoma. 
Although oxaliplatin has neurotoxic side effects, ototoxic side 
effects have rarely been observed (  1  ). Oxaliplatin is rapidly and 
non-enzymatically biotransformed to other molecular species (  6  ,  7  ) 
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     Background     Cisplatin is a cornerstone anticancer drug with pronounced ototoxicity, whereas oxaliplatin, a platinum 
derivative with a different clinical profile, is rarely ototoxic. This difference has not been explained.   
     Methods     In HCT116 cells, cisplatin (20   µ  M)-induced apoptosis was reduced by a calcium chelator from 9.9-fold induc-
tion (95% confidence interval [CI] = 8.1- to 11.7-fold), to 3.1-fold induction (95% CI = 2.0- to 4.2-fold) and by 
superoxide scavenging from 9.3-fold (95% CI = 8.8- to 9.8-fold), to 5.1-fold (95% CI = 4.4- to 5.8-fold). A 
guinea pig model (n = 23) was used to examine pharmacokinetics. Drug concentrations were determined by 
liquid chromatography with post-column derivatization. The total platinum concentration in cochlear tissue 
was determined by inductively coupled plasma mass spectrometry. Drug pharmacokinetics was assessed 
by determining the area under the concentration  –  time curve (AUC). Statistical tests were two-sided.   
     Results     In HCT116 cells, cisplatin (20   µ  M)-induced apoptosis was reduced by a calcium chelator from 9.9-fold 
induction (95% confidence interval [CI] = 8.1- to 11.7-fold to 3.1-fold induction) (95% CI = 2.0- to 4.2-fold) 
and by superoxide scavenging (from 9.3-fold, 95% CI = 8.8- to 9.8-fold, to 5.1-fold, 95% CI = 4.4- to 
5.8-fold). Oxaliplatin (20   µ  M)-induced apoptosis was unaffected by calcium chelation (from 7.1- to 6.2-fold 
induction) and by superoxide scavenging (from 5.9- to 5.6-fold induction). In guinea pig cochlea, total 
platinum concentration (0.12 vs 0.63   µ  g/kg, respectively,   P   = .008) and perilymphatic drug concentrations 
(238 vs 515   µ  M × minute      , respectively,   P   < .001) were lower after intravenous oxaliplatin treatment 
(16.6 mg/kg) than after equimolar cisplatin treatment (12.5 mg/kg). However, after a non-ototoxic cisplatin 
dose (5 mg/kg) or the same oxaliplatin dose (16.6 mg/kg), the AUC for perilymphatic concentrations was 
similar, indicating that the two drugs have different cochlear pharmacokinetics.   
     Conclusion     Cisplatin- but not oxaliplatin-induced apoptosis involved superoxide-related pathways. Lower cochlear 
uptake of oxaliplatin than cisplatin appears to be a major explanation for its lower ototoxicity.   
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and one or more of these species may contribute to its cytotoxicity 
(  8  ). The terminal half-life of oxaliplatin in humans is approxi-
mately 14 minutes (  9  ) and that of cisplatin is 25 minutes (  10  ). 
Many studies (  11  ,  12  ) have demonstrated different cellular effects 
of cisplatin and oxaliplatin, with a main focus on differences in 
DNA damage responses and gene expression proﬁ  les that can be 
attributed to the more bulky oxaliplatin-derived DNA adducts. 
  Although platinum-based drugs are generally considered to be 
DNA-damaging agents, evidence is accumulating that nucleus- 
independent mechanisms of cytotoxicity are also important. 
Experiments with enucleated cytoplasts have clearly demonstrated 
that molecular events triggered by cisplatin, which are independent 
of nuclear DNA, lead to activation of caspases 3 and 7 (  13  ,  14  ) or 
other yet unidentiﬁ  ed proteases (ie, DEVDases) that are speciﬁ  c for 
the amino acid sequence Asp-Glu-Val-Asp (ie, DEVD). Such events 
are likely to contribute to the therapeutic efﬁ  cacy and side effects of 
platinum-based drugs. In particular, side effects that are independent 
of DNA damage may be more pronounced in terminally differenti-
ated cells such as those in the organ of Corti because these cells no 
longer replicate and thereby have very low DNA turnover, which 
should minimize the risks and consequences of DNA damage. 
  The thioredoxin system plays a major role in redox regulatory 
and antioxidant cellular systems; the thioredoxin system consists 
of isoforms of the 12-kDa redox-active thioredoxin protein and 
the selenoprotein thioredoxin reductase. Thioredoxin reductases 
use     -nicotinamide adenine dinucleotide phosphate (NADPH) to 
reduce the active site disulﬁ  de of thioredoxin. The reduced thi-
oredoxin is thereby enabled to support the activity of various 
thioredoxin-dependent antioxidant enzymes, including peroxi-
redoxins and methionine sulfoxide reductases (  15    –    18  ). This enzy-
matic network is very important for health and disease in general 
(  16  ,  19  ) and for cancer development or treatment in particular 
(  20  ,  21  ). Indeed, expression of thioredoxin reductase is required for 
the formation of speciﬁ   c types of tumors, as demonstrated 
via xenograft experiments with lung adenocarcinoma cells (  22  ). 
Because of its dependence on a highly reactive nucleophilic and 
solvent-accessible selenocysteine residue (  23  ,  24  ), thioredoxin 
reductase is inhibited by various electrophilic anticancer agents, 
including platinum-based drugs (  25  ,  26  ). Inhibition of this enzyme 
with a platinum-based drug may lead to cytotoxic effects that result 
from inhibition of the entire thioredoxin system (  16  ,  20  ,  21  ) and, 
more speciﬁ  cally, from the gain of a cell-death  –  provoking pro-
oxidant function in the cisplatin-derivatized enzyme, which forms 
so-called selenium-compromised thioredoxin reductase-derived 
apoptotic proteins (SecTRAPs) (  27  ). 
  We thus hypothesized that differential involvement and targeting 
of redox systems, in particular thioredoxin reductase, may be a 
mechanistically important difference in the effectiveness of cisplatin 
and oxaliplatin. We ﬁ  rst tested this hypothesis in cultured human 
colon carcinoma cells by investigating whether cellular thioredoxin 
reductase is differentially targeted by cisplatin and oxaliplatin and 
whether redox-related events are equally involved with both drugs. 
Second, we assessed if thioredoxin reductase is present in the mam-
malian cochlea, so that it could be a possible cochlear target protein 
for cisplatin. Derivatization of thioredoxin reductase with cisplatin 
could clearly lead to increased oxidative stress, which has been dem-
onstrated previously to be a causative factor for ototoxicity (see 
above). It should be noted that, in contrast to cultured colon carci-
noma cells, the cellular targets in the cochlea for cisplatin (ie, the 
organ of Corti, stria vascularis, and spiral ganglion neurons) contain 
terminally differentiated cells, in which non-DNA  –  related cisplatin 
targets may be especially important mediators of the cisplatin-
induced ototoxicity. Finally, the mechanisms responsible for ototox-
icity are likely to be multifactorial and to include kinetics and cellular 
uptake in addition to cellular pathways of apoptosis and cell death 
induction. We therefore also examined whether differential pharma-
cokinetic proﬁ  les could explain the differences in ototoxicity between 
cisplatin and oxaliplatin in vivo. For these experiments, we used the 
well-  characterized guinea pig model for inner ear studies (  28  ) to 
sample ﬂ  uid from the scala tympani of the cochlea. The samples were 
analyzed with a selective and sensitive method (liquid chromatogra-
phy with post-column derivatization) to obtain concentrations of the 
active drugs (  29  ). We reasoned that, with these experiments, we 
would be able to explain the considerably lower ototoxicity of oxali-
platin than of cisplatin. 
    Materials and Methods 
    Drugs, Chemicals, and Reagents 
  For all studies, cisplatin was from Bristol-Myers Squibb 
Pharmaceuticals (Platinol, New York, NY; 1 mg/mL). For in vitro 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Chemotherapy with cisplatin is often associated with hearing loss 
(ie, ototoxicity), but treatment with oxaliplatin, another platinum-
based chemotherapeutic agent, is rarely associated with ototoxic 
side effects.         
    Study design 
  A cancer cell line was used to investigate whether inhibitors of 
superoxide- and calcium-mediated signaling could alter cisplatin- 
or oxaliplatin-induced apoptosis. A guinea pig model was used to 
examine cisplatin- or oxaliplatin-induced ototoxicity and pharma-
cokinetics of both drugs in the cochlea.   
    Contribution 
  In cancer cells, cisplatin-induced apoptosis, but not oxaliplatin- 
induced apoptosis, was reduced by lowering the concentration of 
calcium ions or superoxide ions. In guinea pig cochlea, total and 
perilymphatic drug concentrations were lower after oxaliplatin 
treatment than after cisplatin treatment and appear to be a major 
explanation for its lower ototoxicity.   
    Implications 
  Additional research is warranted into the mechanisms of how 
treatment with cisplatin vs oxaliplatin leads to ototoxicity.   
    Limitations 
  It is not clear how cytotoxicity in cancer cells relates to ototoxicity 
in vivo. Drug concentrations in the perilymph over time could not 
be measured in an individual guinea pig because only one sample 
can be taken from each cochlea. Human subjects and guinea pigs 
may or may not have the same cochlear pharmacokinetics. 
    From the Editors       
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studies, oxaliplatin was from Sigma-Aldrich Chemicals (Steinheim, 
Germany). For in vivo studies, oxaliplatin was from Sanofi-Aventis 
(Eloxatin, Paris, France; 5 mg/mL). All other chemicals used were 
of analytical grade or higher and were purchased from Sigma-
Aldrich Chemicals, unless otherwise specified.   
    Cells and Cell Culture 
  HCT116 human colon carcinoma cells from Johns Hopkins 
University, Baltimore, MD, were cultured in McCoy  ’  s 5A medium 
(Gibco/Invitrogen Ltd, Paisley, UK), supplemented with 10% 
fetal calf serum, penicillin (100 U/mL), streptomycin (100   µ  g/mL), 
and 2 mM   l  -glutamine. For all experiments involving monolayer 
cell culture, cells were seeded at 24    000 cells per cm  2   in 200   µ  L of 
medium per well in microtiter plates or in 10 mL in tissue culture 
plates for flow cytometry. After overnight incubation, the superna-
tants were replaced with fresh medium with or without experimen-
tal drugs, as indicated.   
    Cytoplast Preparation and Apoptosis Measurement 
  Cytoplasts were prepared essentially as described previously (  14  ). 
Briefly, cultured HCT116 human colon carcinoma cells were har-
vested, resuspended in 12.5% Ficoll containing complete medium 
and cytochalasin B at 10   µ  g/mL to destabilize cellular microfila-
ments, and incubated for 30 minutes at 37°C. A 1-mL suspension 
of these cells was then layered onto a density gradient prepared in 
ultracentrifuge tubes as follows: 1 mL of 25% Ficoll, 1 mL of 17% 
Ficoll, 0.25 mL of 16% Ficoll, and 0.25 mL of 15% Ficoll. The 
gradient was prepared in complete medium supplemented with 
cytochalasin B (10   µ  g/mL). After centrifugation in a prewarmed 
(32°C) Sorvall 90SE rotor for 60 minutes at 30    000   g  , the enucle-
ated cytoplasts were washed in medium and cultured for 16 hours 
in 10-cm tissue culture plates containing 8 mL of medium with 
or without cisplatin, as indicated. The cytoplasts were then 
stained with propidium iodide (5   µ  g/mL in phosphate-buffered 
saline [PBS] containing digitonin at 50   µ  g/mL) and fluorescein 
isothiocyanate-labeled antibody against caspase-3 (1:50 dilution) 
or against caspase-cleaved cytokeratin-18 (M30 antibody, 1:100 
dilution), both courtesy of PEVIVA AB (Stockholm, Sweden), and 
analyzed by flow cytometry for the presence of these labeled anti-
bodies in individual cells as a measure of apoptosis. Because cyto-
plasts have approximately 10% of the level of propidium iodide 
staining of intact cells, the populations of cytoplasts and contami-
nating intact cells could be identified by propidium iodide staining 
and separated by electronic gating. This procedure ensures that 
apoptosis was assessed separately in cytoplasts and intact cells.   
    Assessment of Cellular Apoptotic Signaling Pathways 
  The involvement of calcium in the apoptotic pathway induced 
by drug treatment was investigated by use of the Ca  2+   chelator 
1,2-bis-(  o  -aminophenoxy)-ethane-  N,N,N  ′  ,N  ′    -tetraacetic acid tet-
raacetyoxymethyl ester (BAPTA-AM; Molecular Probes Invitrogen, 
Paisley, UK). The involvement of reactive oxygen species was 
investigated by use of the superoxide anion scavenger Tiron (ie, 
4,5-dihydroxy-1,3-benzenedisulfonic acid, disodium salt monohy-
drate; Sigma-Aldrich Chemicals). HCT116 cells were incubated 
with cisplatin or oxaliplatin in the presence or absence of 
BAPTA-AM at 10   µ  M or Tiron at 5 mM. After a 24-hour treat-
ment, apoptosis was assessed in total cell culture lysates with 
Apoptosense (PEVIVA AB), an enzyme-linked immunosorbent-
type assay with an antibody that specifically recognizes a neoepitope 
created by the caspase-specific cleavage of cytokeratin-18 to stable 
43- and 17-kDa fragments (  30  ).   
    Measurement of Cellular Thioredoxin Reductase Activity 
  Cultured HCT116 cells were used to investigate the effect of 
cisplatin or oxaliplatin on cellular thioredoxin reductase activity. 
Cells were preincubated for 30 minutes with the Ca  2+   chelator 
BAPTA-AM (10   µ  M) or the superoxide anion scavenger Tiron (5 
mM) before addition of cisplatin or oxaliplatin as indicated. After 
incubations for 2, 4, or 8 hours, cells were harvested, washed with 
PBS, and centrifuged at 800   g   for 5 minutes at 4°C. The resulting 
cell pellet was resuspended in extraction buffer (50 mM Tris  –
  HCl at pH 7.5, 2 mM EDTA, 0.5 mM phenylmethylsulfonyl 
fluoride, and 0.5% Nonidet P-40) and the cells were then lysed 
by three cycles of freezing and thawing. Cell extracts were 
cleared by centrifugation (16    000   g   at 4°C for 5 minutes). 
Supernatants were collected and their protein concentrations 
were assessed with the Bradford method (Bio-Rad Laboratories, 
Inc, Hercules, CA) with bovine serum albumin as the protein 
standard. Thioredoxin reductase activity was subsequently deter-
mined in these supernatants as described previously (  31  ) by use 
of the endpoint thioredoxin-  catalyzed insulin reduction assay 
(slightly modified and applied to microtiter plates). In brief, cell 
extracts containing 15   µ  g of total protein in 10   µ  L of extraction 
buffer were incubated with 12   µ  g of recombinant mutant C62S 
and C73S human thioredoxin (  32  ), 297   µ  M insulin, 1.3 mM 
NADPH, 85 mM HEPES buffer (pH 7.6), and 13 mM EDTA 
for 40 minutes at 37°C (in a total volume of 50   µ  L). The reaction 
was stopped by the addition of 200   µ  L of 8 M guanidine-HCl 
(dissolved in 0.2 M Tris  –  HCl, pH 8.0) containing 1 mM 5,5´-
dithiobis(2-nitrobenzoic acid) and the absorbance at 412 nm was 
measured with a VersaMax microplate reader (Molecular Devices 
Corporation, Sunnyvale, CA).   
    In Vivo Studies With Guinea Pigs 
  Forty-two guinea pigs from a commercially available wild-living 
strain (Duncan  –  Hartley) of both sexes and about 9 weeks of age 
were housed at the animal facility and kept in enrichment cages 
with nesting material, at a room temperature of 21°C with a 
12-hour light  –  dark cycle and free access to food and tap water. 
The guinea pigs were anesthetized with an intramuscular injection 
of ketamine (Ketalar, Pfizer, Stockholm, Sweden) at 40 mg/kg and 
xylazine (Rompun vet, Bayer, Stockholm, Sweden) at 10 mg/kg 
before the surgical procedure and kept under anesthesia through-
out the experiment by use of additional doses of ketamine at 
25 mg/kg. Lidocaine (Xylocain, AstraZeneca, Södertälje, Sweden) 
was given locally before surgery. At the conclusion of the experi-
ment, the animals were decapitated while still under anesthesia. 
For all surgical procedures, guinea pigs were placed on a Harward 
homeothermic surgical table and a constant rectal temperature of 
38°C was maintained. Care and use of the animals reported in this 
study were approved by the local Animal Care and Use Committee, 
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    Immunohistochemistry 
  Thioredoxin reductase expression was investigated immunohis-
tochemically in cochlea from four guinea pigs that were not treated 
with a platinum-based drug. Guinea pigs used for immunohis-
tochemistry were deeply anesthetized as described above and 
decapitatated. The temporal bones were removed. The cochlea 
was opened at the round and oval windows, and the perilymphatic 
space was perfused with 4% paraformaldehyde in PBS. Cochleas 
were fixed in 4% paraformaldehyde in PBS for 1 hour at room 
temperature and stored in 0.5% paraformaldehyde in PBS at 4°C. 
After decalcification, tissues were embedded in paraffin and sec-
tioned with a microtome. Four to six cochlear sections of 5   µ  m 
from every guinea pig were mounted per slide. The tissue sections 
were deparaffinated, boiled in diluted antigen-  unmasking solution 
(Vector Laboratories, Burlingame, CA) for 10 minutes, and then 
cooled to room temperature for 20 minutes. After washing in PBS, 
sections were incubated with blocking serum (5% goat serum albu-
min in PBS) for 30 minutes at room temperature to minimize 
background staining. One separate slide and one section on each 
slide were used as negative controls. Rabbit anti-rat thioredoxin 
reductase 1 polyclonal antibodies (Upstate Technology, New 
York, NY; diluted 1:100 and 1:1000) were used as a primary anti-
body; all results shown used the 1:1000 dilution. Negative controls 
were incubated in PBS alone. To confirm the specificity, one sec-
tion of each slide was incubated with primary antibody that had 
been preincubated with recombinant rat thioredoxin reductase 1 
protein for 1 hour at 37°C. All sections overnight at 4°C. After 
washing with PBS, bound antibodies were visualized by use of 
indocarbocyanine (Cy3, red color)-conjugated goat anti-rabbit 
antibody (Jackson Immuno Research Laboratories Inc, West 
Grove, PA, diluted 1:1000) applied for 60 minutes at room tem-
perature. After washing with PBS, the nuclei of all sections were 
counterstained with 4  ′  ,6-diamidino-2-phenylindole (blue color; 
diluted 1:10    000) for 1 minute and sections were then mounted. 
Slides from the whole cochleas were analyzed by fluorescence 
microscopy. Specificity was verified by use of sections not stained 
with primary antibody for negative control, as described previously 
for experiments in hamsters in which the same primary antibodies 
were used (  33  ), as well as preabsorption of primary antibodies to 
the antigen (see above).   
    Assessment of Hair Cell Toxicity and Total Platinum 
Concentration 
  We used a total of 15 pigmented guinea pigs of both sexes with a 
weight of 313 ± 17 g (mean ± SD). The guinea pigs were divided into 
three groups: group I (n = 5) received a single dose of oxaliplatin at 16.6 
mg/kg intrave  nously, group II (n = 5) received cisplatin at 12.5 mg/
kg intravenously, and group III (n = 5) received cisplatin at 5 mg/kg 
intravenously. We used Tucker-Davis Technologies equipment 
(Gainesville, FL) to obtain thresholds for the auditory brain 
stem response from anesthetized animals before treatment with 
cisplatin or oxaliplatin and 96 hours after treatment. The shift in 
the auditory brain stem response threshold was calculated as the 
difference between electrophysiological hearing thresholds 
obtained before and after drug treatment and expressed in dB (  34  ). 
After the final auditory brain stem response was measured, the 
animals were decapitated under deep anesthesia and the temporal 
bones were immediately removed from the rest of the skull. The 
perilymphatic space was opened, perfused with 4% paraformalde-
hyde in PBS, and fixed in 4% paraformaldehyde in PBS for 1 hour 
at room temperature, and then stored in 0.5% paraformaldehyde 
in PBS at 4°C. 
  The right cochlea from each guinea pig was rinsed in PBS, the 
basilar membrane with the organ of Corti was exposed by removing 
the bone and surrounding tissue, and the remaining cells were 
labeled with phalloidin (1:200 dilution) for 45 minutes in the dark at 
room temperature to visualize actin in the stereocilia of the hair 
cells. Inner and outer hair cells were counted in discrete steps from 
apex to base under a Zeiss ﬂ  uorescence microscope. The criterion 
for hair cell loss was scar formation. The percentage of missing hair 
cells per 1 mm was calculated. The loss of hair cells was presented 
in cochleograms, which plot the percentage of missing hair cells 
against the distance from the round window (ie, one of two openings 
in the cochlear bone that connect the inner ear to the middle ear). 
  The left cochlea from each animal given cisplatin (12.5 mg/kg) 
or oxaliplatin (16.6 mg/kg) was used to determine the total plati-
num content in the cochlear tissue. The entire basilar membrane 
including the organ of Corti and stria vascularis was dissected. 
Analysis of total platinum in cochlear tissue was performed by use 
of inductively coupled plasma mass spectrometry by a certiﬁ  ed 
method (Analytica AB, Luleå, Sweden).   
    Pharmacokinetics 
  A total of 23 albino guinea pigs of both sexes were used in the 
pharmacokinetic experiment. The guinea pigs were divided 
into two groups. Group I (n = 13), with a weight of 442 ± 61 g 
(mean ± SD), received a single intravenous dose of oxaliplatin 
(16.6 mg/kg at 5 mg/mL) and group II (n = 10), with a weight of 
326 ± 30 g (mean ± SD), received a single intravenous dose of 
cisplatin (5 mg/kg at 1 mg/mL). From every guinea pig, four blood 
samples, two samples of cerebrospinal fluid, and one sample of scala 
tympani perilymph from the right and left cochlea, respectively, 
were drawn within a total time range of 1.5  –  90 minutes (at 1.5, 5, 
10, 15, 20, 30, 40, 50, 60, and 90 minutes) after administration of 
the drug. Both internal jugular veins were exposed and a catheter 
was inserted on each side. To avoid blood clots, approximately 
5 IU of sodium heparin in 0.1 mL of saline was administrated in 
each catheter. One catheter was used to deliver drug and the other 
was used to obtain blood samples. The bone surrounding the 
cochlea was resected on both sides by use of a dorsolateral 
approach, and a small hole was drilled in the basal turn of the 
cochlea to aspirate the scala tympani perilymph. The occipital 
bone was opened and the dura mater was exposed. A small hole was 
made in the dura mater so that clear cerebrospinal fluid from the 
subarachnoid space could be sampled. A small hook held up the 
dura to avoid mixing drain fluid and blood with cerebrospinal 
fluid. Oxaliplatin or cisplatin was given intravenously for 23 ± 10 
seconds (mean ± SD). Every 0.35-mL blood sample removed was 
replaced with 0.35 mL of saline. A 10-  µ  L syringe was attached to 
a micromanipulator, and clear cerebrospinal fluid (1  –  10   µ  L) was 
aspirated from the subarachnoid space, placed in an Eppendorf 
tube, and promptly frozen on dry ice. 
  A 1-  µ  L syringe was placed in a Nagai micromanipulator and 
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turn of the cochlea. We quickly sampled the perilymph to reduce 
spillover of scala tympani perilymph ﬂ  uid and thereby avoid 
contamination of cerebrospinal ﬂ  uid through the cochlear aque-
duct (  35  ). One 1-  µ  L sample of scala tympani perilymph was aspi-
rated under careful inspection. Each sample was placed in a vial 
containing 25 or 50   µ  L of H  2  O (MilliQ grade) and then directly 
frozen on dry ice. 
  Blood samples were collected in heparinized tubes (Microtainer, 
Becton Dickinson, Franklin Lakes, NJ), kept on ice, and subjected 
to centripetal ultraﬁ  ltration within 1 hour by use of a ﬁ  lter with a 
10    000 molecular weight cutoff (Centrisart, Sartorius AG, Göttingen, 
Germany) for 20 minutes at 4000   g   at 4°C. The ultraﬁ  ltrate was 
promptly frozen on dry ice in an Eppendorf tube. As internal con-
trols, known amounts of cisplatin or oxaliplatin were added to 
blood samples from untreated guinea pigs and treated as outlined 
above. All samples were stored at     80°C until analysis, which 
occurred within 3 weeks. Liquid chromatography with post- 
column derivatization, as described previously (  29  ), was used to 
determine the concentration of oxaliplatin. The cisplatin concen-
tration was determined by following the same method but with 
modiﬁ   cations for the monohydrated complex of cisplatin, as 
described previously (  36  ).   
    Pharmacokinetic Evaluation 
  We used the time  –  concentration data for calculations. The area 
under the concentration  –  time curve (AUC) was determined by the 
trapezoidal rule. Terminal elimination half-lives of oxaliplatin and 
cisplatin in blood were determined by use of WIN NONLIN ver-
sion 1.5 SCI (Statistical Consulting Inc, Cary, NC).   
    Statistical Analysis 
  Statistical significance in the experiments with cultured tumor cells 
was analyzed with the Wilcoxon rank test. The variability of AUC 
(a measure of drug exposure) in the pharmacokinetic studies was 
determined according to the principles given by Yuan (  37  ), with a 
subsequent posttest with the Tukey  –  Kramer multiple comparison 
test. Differences in terminal half-life after oxaliplatin (16.6 mg/kg) 
and cisplatin (5 mg/kg) treatment and concentrations of total plati-
num in cochlear tissues after oxaliplatin (16.6 mg/kg) and cisplatin 
(12.5 mg/kg) treatment were assessed with the Mann  –  Whitney 
  U   test. All statistical tests were two-sided. Differences for which 
  P   values were less than .05 were considered to be statistically 
significant.     
    Results 
    Apoptosis in Colon Carcinoma Cells Treated With 
Cisplatin and Oxaliplatin 
  Because human HCT116 colon carcinoma cells show fairly similar 
growth inhibition responses to cisplatin and oxaliplatin, these cells 
were used to compare apoptosis induction by the two drugs. We 
treated these cells with cisplatin or oxaliplatin (each at 10  –  30   µ  M) 
for 24 hours and assessed apoptosis by determining the levels of a 
neoepitope on stable cytokeratin-18 fragments generated specifi-
cally by DEVDase cleavage (notably caspase-3 and -7) (  30  ). We 
found that cisplatin and oxaliplatin induced fairly similar levels of 
apoptosis in human HCT116 colon carcinoma cells. Thus, 10, 20, 
and 30   µ  M oxaliplatin induced 3.9-fold (95% confidence interval 
[CI] = 3.7- to 4.1-fold), 5.9-fold (95% CI = 5.3- to 6.5-fold), and 
7.5-fold (95% CI = 5.8- to 9.2-fold) increased levels of apoptosis, 
respectively, compared with background levels, whereas cisplatin 
at 10, 20, and 30   µ  M induced 3.7-fold (95% CI = 3.1- to 4.3-fold), 
8.3-fold (95% CI = 7.2- to 9.4-fold), and 9.3-fold (95% CI = 
8.6- to 10.0-fold), respectively (  Figure 1, A  ). For comparison, after 
24 hours of treatment, 20   µ  M cisplatin had induced approximately 
50% nuclear fragmentation, which is typically indicative of apop-
tosis, as determined by fluorescence microscopy by counting of 
cells stained with ethidium bromide to visualize intact and frag-
mented nuclear DNA, respectively (data not shown).         
  We have shown previously (  38  ) with a melanoma cell line that 
cisplatin induced increased cytosolic Ca  2+   levels within 1 hour after 
its addition and that apoptosis was inhibited by at least 50% by the 
addition of Ca  2+   chelators. In the present study, we investigated this 
Ca  2+   requirement in HCT116 cells and found that co-treatment 
with the Ca  2+   chelator BAPTA-AM at 10   µ  M reduced 20   µ  M 
cisplatin-induced apoptosis from 9.9-fold above (95% CI = 8.1- to 
11.7-fold) to 3.1-fold (95% CI = 2.0- to 4.2-fold) above back-
ground levels (  Figure 1, B  ). By contrast, apoptosis induced by 
20   µ  M oxaliplatin (7.1-fold above background, 95% CI = 6.0- to 
8.2-fold) was not affected by co-treatment with the calcium chela-
tor BAPTA-AM (6.2-fold above background, 95% CI = 5.4- to 
7.0-fold) (  Figure 1, B  ). Thus, cisplatin and oxaliplatin induce 
apoptosis through different pathways with differential involve-
ment of Ca  2+  . 
  Cisplatin-induced ototoxicity involves the production of reac-
tive oxygen species (  2  ). We thus investigated the involvement of 
reactive oxygen species in cisplatin-induced and oxaliplatin- 
induced cytotoxicity in HCT116 cells by adding the superoxide 
anion scavenger Tiron (5 mM) to the cell cultures concomitantly 
with the platinum drug. We found that Tiron treatment reduced 
cisplatin- but not oxaliplatin-induced apoptosis (  Figure 1, C  ). That 
is, Tiron reduced cisplatin-induced apoptosis from 9.3-fold above 
background (95% CI = 8.8- to 9.8-fold) to 5.1-fold (95% CI = 4.4- 
to 5.8-fold), whereas oxaliplatin-induced apoptosis was marginally 
reduced from 5.9-fold (95% CI = 4.7- to 7.1-fold) to 5.6-fold (95% 
CI = 5.3- to 5.9-fold). In addition, Tiron reduced cisplatin-induced 
apoptosis also in enucleated HCT116 cells (ie, cells from which 
nuclei were removed before drug treatment) (  Figure 1, D  ). Thus, 
the superoxide-dependent apoptotic pathway induced by cisplatin 
appears to be, at least partially, independent of DNA damage.   
    Inhibition of Thioredoxin Reductase by Cisplatin and 
Oxaliplatin in HCT116 Colon Carcinoma Cells and Its 
Expression in the Cochlea 
  We investigated whether thioredoxin reductase inhibition by plati-
num-based drugs was associated with the induction of oxidative 
stress in HCT116 cells. We first determined that 8 hours of treat-
ment with 80  –  100   µ  M cisplatin or oxaliplatin was required to inhibit 
more than 80% of total cellular thioredoxin reductase activity (data 
not shown). Because either 20   µ  M cisplatin or 20   µ  M oxaliplatin 
induced detectable apoptosis after 12 hours (data not shown), total 
inhibition of thioredoxin reductase activity is apparently not 
required for apoptosis induction. However, treatment with 20   µ  M 
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activity (  Figure 2  ). Cellular thioredoxin reductase activity was inhib-
ited statistically significantly more by cisplatin than by oxaliplatin 
(  P   = .001). Co-treatment of cells with Tiron and cisplatin did not 
block the inhibition of thioredoxin reductase activity (data not 
shown) and, although not conclusive evidence, the result is in line 
with thioredoxin reductase being part of cisplatin-specific effects 
on cytosolic redox systems.         
  We used immunohistochemistry to determine whether thiore-
doxin reductase was expressed in the cochlea of guinea pigs. We 
found evidence of immunoreactivity for this protein in the cochlea 
of the guinea pig. The results show that thioredoxin reductase 1 
was expressed in the organ of Corti (inner and outer hair cells), in 
the lateral wall (stria vascularis and ﬁ  brocytes of the spiral liga-
ment), and in the neurons of spiral ganglion (  Figure 3  ). The 
immunoreactivity was mainly localized to the cytosol or mem-
branes and not the nuclei of the cells, as shown by the nuclear 
counterstaining. Negative controls of cochlea tissue sections 
stained with antibodies that had been preincubated with pure thi-
oredoxin reductase showed markedly lower staining, supporting 
the speciﬁ  city of the polyclonal antibodies against rat thioredoxin 
reductase 1 used in this study and the cross-reactivity of this anti-
body with the guinea pig orthologue of thioredoxin reductase.         
  Thus, apoptosis induced by cisplatin and oxaliplatin differed in 
regard to the involvement of Ca  2+   cations and superoxide anions; 
cisplatin-induced apoptosis clearly involved both of these param-
eters, whereas oxaliplatin-induced apoptosis clearly showed less or 
no involvement of redox-dependent processes because it was unaf-
fected by chelation or scavenging of either of these molecular spe-
cies. The results also support the hypothesis that thioredoxin 
reductase targeting, at least in part, contributes to cisplatin cyto-
toxicity in tumor cells and in the cochlea.   
    Ototoxicity and Pharmacokinetics of Cisplatin and 
Oxaliplatin 
  Because the ability of oxaliplatin to induce toxic effects on the 
cochlea and to enter cochlear fluids of guinea pigs had, to our knowl-
edge, not been investigated, we studied the electrophysiological 
hearing thresholds and hair cell loss after oxaliplatin treatment. We 
also determined the uptake of oxaliplatin in scala tympani perilymph 
to compare these values with those of cisplatin. All 15 guinea pigs 
used to assess ototoxicity were tested for auditory sensitivity before 
and after drug treatment. An intravenous cisplatin dose of 12.5 mg/
kg produced pronounced hair cell loss and total deafness (ie, no 
discernible electrophysiological wave response at the three tested 
frequencies 6.3, 12.5, and 20 kHz). An equimolar dose of intrave-
nous oxaliplatin (16.6 mg/kg), however, did not produce any loss of 
inner or outer hair cells (  Figure 4  ) and produced only minor changes 
of the pretreatment auditory brain stem thresholds. The change of 
the auditory brain stem threshold (the difference between the post-
treatment threshold obtained 96 hours after drug administration and 
Figure   1. Apoptotic signaling induced by cisplatin 
and oxaliplatin. A) Comparison of apoptosis 
induced by cisplatin and oxaliplatin (each at 10, 
20, or 30 µM). Cells were treated in triplicate sam-
ples (n  =  at least four separate experiments). B) 
Requirement for calcium in apoptosis induced by 
cisplatin but not by oxaliplatin (each at 20 µM). The 
calcium chelator 1,2-bis-(o-aminophenoxy)-ethane-
N,N,N′,N′-tetraacetic acid tetraacetyoxymethyl 
ester (BAPTA) was added at 10 µM, as indicated. 
Triplicate samples were examined. Data from one 
representative experiment of three are shown; all 
results were similar. C) Requirement for reactive 
oxygen species in apoptosis induced by cisplatin 
but not by oxaliplatin (each at 10 or 20 µM). The 
superoxide anion scavenger Tiron was added at 
5 mM, as indicated. Triplicate samples were exam-
ined (n  =  two separate experiments). A–C) HCT116 
human colon cancer cells were incubated with 
drugs as indicated for 24 h, after which accumu-
lated apoptosis levels were assessed with the 
Apoptosense assay of DEVDase activity, i.e., activ-
ity of proteases recognizing the amino acid 
sequence Asp-Glu-Val-Asp (DEVD). Error bars are 
95% conﬁ   dence intervals. Data are presented as 
fold increase in apoptosis compared with back-
ground levels of apoptosis in nontreated cells. 
Cisplatin induces superoxide-dependent apoptosis 
also in the absence of nuclear DNA damage. 
D) Cytoplasts (ie, enucleated HCT116 cells) were 
prepared, and duplicate cultures were treated with 
cisplatin (10, 20, or 40 µM) or with Tiron (5 mM), as 
indicated. Apoptosis in cytoplasts was measured 
as DEVDase activity by ﬂ  ow cytometry and data 
are presented as the percentage of DEVDase activ-
ity in untreated controls. Data are the mean of two 
experiments.jnci.oxfordjournals.org    JNCI | Articles 43
the pretreatment threshold measured before drug administration) 
was 11 dB at a frequency of 6.3 kHz (95% CI = 3 to 19 dB), 6 dB at 
12.5 kHz (95% CI = 2 to 14 dB), and 14 dB at 20 kHz (95% CI = 3 
to 25 dB), as measured 96 hours after drug administration. Guinea 
pigs treated with cisplatin at 5 mg/kg had normal hearing and no 
apparent loss of hair cells (data not shown).         
  Concentrations of oxaliplatin and cisplatin in blood, cerebrospi-
nal ﬂ  uid, and scala tympani perilymph in the cochlea after adminis-
tration of oxaliplatin at 16.6 mg/kg or cisplatin 5 mg/kg, respectively, 
were then determined (  Figures 5   and   6  ). The AUC values for the 
drugs in the perilymph were similar (  P   > .05) for guinea pigs treated 
with low-dose cisplatin (5 mg/kg; 202   µ  M × minute, 95% CI = 167 
to 228   µ  M × minute) or with higher dose oxaliplatin (16.6 mg/kg; 
238   µ  M × minute, 95% CI = 202 to 262   µ  M × minute), although the 
molar cisplatin dose (16.7   µ  mol/kg) was only 40% of the molar dose 
of oxaliplatin (41.8   µ  mol/kg). The uptake of oxaliplatin into scala 
tympani perilymph was more rapid than the uptake of cisplatin, 
with the maximum oxaliplatin concentration of 4.57   µ  M (95% CI = 
1.81 to 7.34   µ  M), which was reached after 15 minutes, compared 
with the maximum cisplatin concentration of 2.95   µ  M (95% CI = 
1.58 to 4.33   µ  M), which was reached after 30 minutes. The peak 
concentrations of both oxaliplatin and cisplatin were found sooner 
in the cerebrospinal ﬂ  uid than in the scala tympani perilymph ﬂ  uid. 
The terminal half-life of oxaliplatin in guinea pig blood (12 min-
utes, 95% CI = 11 to 14 minutes) was shorter than that of cisplatin 
(33 minutes, 95% CI = 27 to 42 minutes).                 
  Concentrations in scala tympani perilymph were determined 
after treatment of guinea pigs with an intravenous equimolar dose 
of either cisplatin (12.5 mg/kg) or oxaliplatin (16.6 mg/kg); the 
concentration of cisplatin was recalculated from previously reported 
data from our laboratory (  5  ). The AUC value was larger for cispla-
tin (515   µ  M × minute, 95% CI = 396 to 587   µ  M × minute) than 
that for oxaliplatin (238   µ  M × minute, 95% CI = 202 to 262   µ  M × 
minute;   P   < .001) (  Figure 7  ). We also examined concentrations of 
platinum in cochlear tissues after oxaliplatin (16.6 mg/kg) and 
cisplatin (12.5 mg/kg) treatment. The total platinum content in 
the cochlear tissue was statistically signiﬁ  cantly higher 96 hours 
after administration of cisplatin (total platinum = 0.63   µ  g/g, 95% 
CI = 0.54 to 0.73   µ  g/g, n = 5) than oxaliplatin (total platinum = 0.12 
  µ  g/g, 95% CI = 0.00 to 0.24   µ  g/g, n = 5) (  P   = .008). These results 
indicate that the pharmacokinetic differences between cisplatin 
and oxaliplatin may be sufﬁ  cient to explain their different ototoxic 
proﬁ  les.             
    Discussion 
  We found differences between the apoptosis signaling induced by 
cisplatin and oxaliplatin in proliferating HCT116 cancer cells, 
with redox-related effects being clearly associated with apoptosis 
induced by cisplatin but not by oxaliplatin under comparable con-
ditions. Although these agents are sometimes regarded as inter-
changeable, these results show that they differ. We also identified 
thioredoxin reductase 1 as a potential target for cisplatin, in par-
ticular, in both HCT116 cells and cochlea. However, the differ-
ences in cochlear kinetics and cellular uptake that we found in the 
hearing end organ are sufficient to explain the difference in ototox-
icity between cisplatin and oxaliplatin. 
  We have previously demonstrated that cisplatin has pronounced 
DNA damage- and nucleus-independent effects (  13  ,  14  ). In addi-
tion, levels of cytosolic Ca  2+   and reactive oxygen species increase by 
50% within 1 hour after cisplatin treatment (  38  ), which is well 
before the onset of p53 accumulation, which occurs approximately 
3 hours after treatment with either drug (M Berndtsson PhD, MSc 
E Hernlund MSc, Shoshan M, PhD; unpublished  observations). In 
this study, we show that, although cisplatin and oxaliplatin induce 
similar levels of apoptosis in cultured HCT116 colon carcinoma 
cells, superoxide anion production and increased levels of intracel-
lular calcium are required for cisplatin-induced but not oxaliplatin-
induced apoptosis. Superoxide anion production was furthermore 
independent of DNA damage, as shown by the effects of cisplatin 
in enucleated cells. DNA-damaging drugs typically act by interfer-
ing with DNA replication (  39  ). However, cells in the organ of 
Corti are terminally differentiated and do not divide. Therefore, 
the apoptotic redox signaling induced by cisplatin in enucleated 
cells may be a possible mechanism of cisplatin-induced ototoxicity. 
It should also be noted that the chloride concentrations in the 
McCoy’s culture medium used for the tumor cells and in the mam-
malian perilymph were in the same range (120 and 110  –  140 mM, 
respectively). Different extracellular chloride concentrations are 
thereby not likely to affect the cisplatin toxicity differently in cell 
culture and in the outer hair cells in the organ of Corti. 
  The involvement of calcium cations and superoxide anions in 
cisplatin-induced apoptosis but not oxaliplatin-induced apoptosis is 
   
    Figure 2    .       Inhibition of cellular thioredoxin reductase 1 (TrxR1) activity 
by cisplatin and oxaliplatin. HCT116 human colon cancer cells were 
treated with 20   µ  M cisplatin or 20   µ  M oxaliplatin for 2 or 4 h. Thioredoxin 
reductase 1 activity was then determined in cell extracts with a thiore-
doxin-coupled endpoint insulin reduction assay (n    =    12 replicates at 2 h; 
n    =    15 replicates at 4 h). Enzyme activity is presented as relative to activ-
ity in the nontreated control. Error bars    =    95% conﬁ  dence  intervals. 
***  P   < .001, as determined with the two-sided Wilcoxon rank test.         44   Articles | JNCI  Vol. 101, Issue 1  |  January 7, 2009
in agreement with the observation that inhibition of thioredoxin 
reductase may affect calcium homeostasis (  40  ,  41  ). Apoptosis was 
also induced by cisplatin despite only partial inhibition of thi-
oredoxin reductase (  Figure 2  ), which might reﬂ  ect the fact that 
cisplatin-derivatized thioredoxin reductase has not only lost thiore-
doxin-reducing activity but also gained a dominant function as pro-
oxidant inducer of cell death (  27  ). This gain of function was 
associated with the conversion of thioredoxin reductase from an 
oxidoreductase with antioxidant activity to a SecTRAP with potent 
superoxide-producing NADPH oxidase capacity after its derivatiza-
tion with cisplatin (  27  ). If SecTRAPs are formed in cisplatin-treated 
cells, then this mechanism may be involved in intracellular superox-
ide production, in prooxidant cell death induction, and also in the 
antiapoptotic effect observed after treatment with the superoxide 
scavanger Tiron. Because of the importance of thioredoxin reductase 
as an enzymatic target contributing to cisplatin toxicity (  20  ,  25    –    27  ), 
because of the weaker inhibitory effect of oxaliplatin on its cellular 
activity, and because of the ﬁ  nding that thioredoxin reductase was 
expressed in the cochlea, we propose that the targeting of thiore-
doxin reductase by cisplatin could contribute to the ototoxicity of 
cisplatin, but this possibility must be investigated further. 
  We have also shown that the lack of major cochlear injury 
during treatment with oxaliplatin is likely explained by the 
pharmacokinetic proﬁ   le of oxaliplatin. There was a striking 
difference between cisplatin and oxaliplatin in the uptakes into 
scala tympani perilymph ﬂ  uid and in total platinum concentra-
tions in cochlear cells. In the inner ear, transport of drugs 
between blood and receptor cells or neural tissue is hindered by 
the presence of barrier cell layers. In analogy with the blood  – 
  brain barrier, the concept of a blood  –  labyrinth barrier is gener-
ally accepted. This barrier can roughly be divided into the 
blood  –  perilymph barrier and the perilymph  –  endolymph 
  Figure 4    .       Drug effects on outer and inner 
hair cells.   A  ) Oxaliplatin.   B  ) Cisplatin. 
Data are presented as cochleograms that 
show the mean loss of hair cells from 
guinea pig cochlea after treatment for 
96 h with intravenously administered 
oxaliplatin (16.6 mg/kg, n    =    5) or cisplatin 
(12.5 mg/kg, n    =    5). The percentage of miss-
      ing inner and outer hair cells along the 
basilar membrane is shown relative to 
the distance from the round window (ie, 
one of two openings in the cochlear bone 
that connect the inner ear to the middle 
ear).   Solid circles      =    inner hair cells;   solid 
squares      =    outer hair cells in the ﬁ  rst row; 
  solid inverted triangles      =    outer hair cells 
in the second row;   solid triangles      =    outer 
hair cells in the third row.   Error bars      =    95% 
conﬁ   dence limits. Ten animals (one 
cochlea from each animal) were used for 
this study.       
  Figure 3    .       Thioredoxin reductase 1 immuno-
reactivity in the cochlea. Fluorescence photo-
micrographs of a guinea pig cochlea showing 
thioredoxin reductase 1 immunoreactivity 
(red) and superimposed images stained with 
4’,6-diamidino-2-phenylindole (DAPI, blue) 
to show nuclei. Due to superimposed images 
the nuclei looks blue-purple.   A  ) Organ of 
Corti with hair cells. SM    =    scala media; 
BM    =    basilar membrane.   Arrows   indicate 
cells that are positive for TrxR1.   B  ) Organ of 
Corti with hair cells. SM    =    scala media; 
BM    =    basilar membrane.   Arrows   indicate 
cells that are positive for thioredoxin 
reductase 1. Blue-purple color indicates 
nuclear staining.   C  ) Stria vascularis. 
BV    =    blood vessel.   Arrow   indicates a cell 
(intermediate cell) that is positive for thiore-
doxin reductase 1. Blue-purple color indi-
cates DAPI nuclear staining.   D  ) Negative 
control. Lateral wall of the cochlea. SM   =    scala 
media, SV    =    stria vascularis, SL    =    spiral liga-
ment.   Arrowheads   indicate cells that are 
negative for thioredoxin reductase 1.   E  ) 
Lateral wall of the cochlea. SM    =    scala media, 
SV    =    stria vascularis, SL    =    spiral ligament. 
  Arrows   indicate cells that are positive for 
thioredoxin reductase 1. Scale bars    =    100   µ  m. 
Four animals (one cochlea from each animal) 
were used for this study.       jnci.oxfordjournals.org    JNCI | Articles 45
barrier, although the functional division between these com-
partments is not fully understood. The blood  –  perilymph bar-
rier, which consists mainly of endothelial cells sealed by tight 
junctions, is most likely the major barrier for pharmacologic 
substances in reaching the sensory epithelium of the hearing 
and balance organs. Cisplatin-induced ototoxicity is known to 
be mediated via injury to several terminally differentiated cel-
lular targets in the cochlea (  42  ), including the marginal and 
intermediate cells of the stria vascularis (  43  ), which is a major 
component of the perilymph  –  endolymph barrier. 
  Our study had several limitations. First, we discovered more 
pronounced oxidative stress and calcium involvement in the cyto-
toxicity of cisplatin than of oxaliplatin in cell cultures, but it is not 
clear if these differences mediate differences in cytotoxicity also in 
vivo. Second, we identiﬁ  ed thioredoxin reductase as a plausible 
cisplatin target in the cochlea but could present no absolute evi-
dence for its involvement in cochlear ototoxicity. This task, which 
is highly demanding methodologically, is beyond the scope of the 
present work but is a major goal of ongoing endeavors. Third, it 
should be noted that it is technically not possible to evaluate the 
scala tympani perilymph concentration time curves of cisplatin 
and oxaliplatin for the individual guinea pigs, because only one 
sample can be taken from each cochlea by aspiration procedures. 
The statistical technique presented by Yuan (  37  ) that we used in 
this analysis is a valuable tool for construction of concentration  –  -
time curves and for calculation of AUC from a group of guinea 
pigs in which only one sample was collected from each cochlea. 
The technique also allows estimation of the variance of AUC in 
such experiments. However, in this analysis, we determined the 
scala tympani perilymph concentrations separately in the left and 
right cochlea to reduce the number of experimental guinea pigs. 
The statistical test used for comparison of the AUC for cisplatin 
and oxaliplatin can thereby be viewed as an estimation procedure, 
as the number of observations was low. However, our conclusions 
   
    Figure 5    .       Pharmacokinetics of oxaliplatin. The concentration of oxalipla-
tin was measured in blood, cerebrospinal ﬂ  uid (CSF), and scala tympani 
perilymph, as indicated, after intravenous administration of oxaliplatin 
(16.6 mg/kg) to guinea pigs. The number of samples per time point per 
treatment is indicated. Data are the mean;   error bars   are 95% conﬁ  -
dence intervals when data from three or more guinea pigs were avail-
able. When the lower conﬁ  dence limit was less than 0, no lower error 
bar is shown (a logarithmic concentration scale is used). Thirteen 
guinea pigs were used for this study.         
   
    Figure 6    .       Pharmacokinetics of cisplatin. The concentration of cisplatin 
was measured in blood, cerebrospinal ﬂ  uid (CSF), and scala tympani 
perilymph, as indicated, after intravenous administration of cisplatin 
(5 mg/kg) to guinea pigs (n    =    10). The number of samples per time point 
per treatment is indicated. Data are the mean;   error bars   are 95% conﬁ  -
dence intervals when data from three or more guinea pigs were avail-
able. When the lower conﬁ  dence limit was less than 0, no lower error 
bar is shown (a logarithmic concentration scale is used). Ten guinea 
pigs were used for this study.         
   
  Figure 7    .       Pharmacokinetics of cisplatin and oxaliplatin. Concentrations 
of the parent drugs were measured in scala tympani perilymph after 
intravenous administration of cisplatin (12.5 mg/kg) or oxaliplatin (16.6 
mg/kg) to guinea pigs (n    =    21 and n    =    13, respectively). The concentra-
tion of cisplatin was recalculated from previously published data (  5  ) 
(with kind permission of Springer Science and Business Media). Data 
are the mean;   error bars   are 95% conﬁ  dence intervals when data from 
three or more guinea pigs were available.       
were further supported by the observed fairly large concentration 
differences between cisplatin and oxaliplatin, as illustrated in 
  Figure 7  . Thus, limited cochlear uptake of oxaliplatin is a major 
explanation for the lower ototoxicity of oxaliplatin than cisplatin. 
These in vivo experiments were performed in guinea pigs, and it 
should not be taken for granted that human subjects have the same 
cochlear pharmacokinetics. For technical and ethical reasons, it is 
impossible to repeat our experiments in human subjects. We do 
believe, though, that the major aspects of our conclusions are valid 
for humans. 
  The AUC of oxaliplatin in the guinea pig perilymph was only 
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administered. It should also be noted that the therapeutic doses of 
oxaliplatin and cisplatin in humans are equimolar (ie, 135 mg/m  2  , 
or 0.34 mmol/m  2  , and 100 mg/m  2  , or 0.33 mmol/m  2  , respec-
tively). Thus, our ﬁ   ndings may represent differences in the 
transport of the two drugs from the blood to the extracellular 
compartments of the cochlea. We can hypothesize that four 
mechanisms may, in various possible combinations, be respon-
sible for the higher cochlear concentration of cisplatin as 
reﬂ  ected by perilymph kinetics. First, the elimination half-life of 
cisplatin was longer than that of oxaliplatin. One would thereby 
expect a higher concentration of cisplatin in the blood for a 
longer period, which would favor its uptake in scala tympani 
perilymph. Second, the permeability of the blood  –  labyrinth bar-
rier might favor inﬂ  ux of cisplatin. Third, increased inﬂ  ux of 
cisplatin to the cochlear extracellular ﬂ  uids might also be pro-
vided by a facilitated inﬂ  ux transport (eg, via a single or a group 
of organic cationic transporters). Fourth, oxaliplatin might also 
have a greater efﬂ  ux from the scala tympani perilymph than 
cisplatin. 
  At equimolar doses, cisplatin (12.5 mg/kg), as expected, had 
severe ototoxic effects in the guinea pig model, whereas oxaliplatin 
(16.6 mg/kg) had minimal ototoxic effects. Reducing the dose of 
cisplatin to 5 mg/kg resulted in a low perilymph concentration of 
drug similar to that of oxaliplatin at 16.6 mg/kg and consequently 
did not induce the drug-induced auditory brain stem threshold 
shift and injury to the outer hair cells. These results strongly indi-
cate that the pharmacokinetic differences between cisplatin and 
oxaliplatin may be sufﬁ   cient to explain their different ototoxic 
proﬁ  les.   
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